<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00372333</url>
  </required_header>
  <id_info>
    <org_study_id>CL-033-III-01</org_study_id>
    <nct_id>NCT00372333</nct_id>
  </id_info>
  <brief_title>IDEA-033 Open Label Study</brief_title>
  <official_title>A Multiple-Dose, Open-Label Safety, Compliance, and Usage Evaluation Study of Epicutaneously Applied IDEA-033 in Joint / Musculoskeletal Pain or Soft Tissue Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDEA AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IDEA AG</source>
  <brief_summary>
    <textblock>
      The main aim of the study is to evaluate safety, efficacy, compliance, and usage of&#xD;
      epicutaneously applied IDEA-033 in joint / musculoskeletal pain or soft tissue inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-centre, one arm, multiple dose, open-label, at home usage study. Adult volunteers&#xD;
      experiencing joint pain, musculoskeletal pain, stiffness, or soft tissue inflammation will be&#xD;
      screened for study participation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>description of AE profile</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in laboratory values</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>IDEA-033 plasma levels</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>visual assessment of skin at target area(s)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>physical exam</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>vital signs</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of efficacy by real time feedback</measure>
  </secondary_outcome>
  <enrollment type="Actual">491</enrollment>
  <condition>Joint Pain</condition>
  <condition>Musculoskeletal Pain</condition>
  <condition>Stiffness</condition>
  <condition>Soft Tissue Inflammation in Designated Target Area(s)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDEA-033</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  at least 18 years or older&#xD;
&#xD;
          -  agree to refrain from chronic usage of NSAIDs or any other analgesics or&#xD;
             anti-inflammatory drugs other than those provided during the course of the study or&#xD;
             documented sporadic concomitant analgesics&#xD;
&#xD;
          -  joint pain, musculoskeletal pain, stiffness, or soft tissue inflammation in designated&#xD;
             target area(s) that are appropriate for self-treatment with a topical analgesic or&#xD;
             where availability of a second person can be guaranteed in case self-treatment is not&#xD;
             possible&#xD;
&#xD;
          -  healthy skin in the target area(s)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known hypersensitivity to IDEA-033 or other NSAIDs&#xD;
&#xD;
          -  history of coagulation disorders&#xD;
&#xD;
          -  history of peptic ulcers or gastric intolerance with NSAIDs&#xD;
&#xD;
          -  urinary tract infection&#xD;
&#xD;
          -  clinically significant renal, hepatic, or gastric disease&#xD;
&#xD;
          -  acute or chronic coexisting illness qualifying for exclusion according to clinical&#xD;
             judgement of the investigator&#xD;
&#xD;
          -  clinical laboratory values outside normal range deemed clinically significant by the&#xD;
             investigator&#xD;
&#xD;
          -  Narcotics-containing products within 7 days of administering IMP&#xD;
&#xD;
          -  Malignancy within the past 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilka Rother</last_name>
    <role>Principal Investigator</role>
    <affiliation>X-pert-med GmbH Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>X-pert med GmbH / Ilka Rother</name>
      <address>
        <city>Gr√§felfing</city>
        <state>Bavaria</state>
        <zip>82166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>September 4, 2006</study_first_submitted>
  <study_first_submitted_qc>September 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2006</study_first_posted>
  <last_update_submitted>March 19, 2009</last_update_submitted>
  <last_update_submitted_qc>March 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2009</last_update_posted>
  <keyword>musculoskeletal pain; soft tissue inflammation; IDEA-033</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

